Loading patent…
AssigneeJanssen Vaccines & Prevention B.V.
InventorsJerôme H. H. V. Custers, Jort Vellinga, Marija Vujadinovic, Esmerelda Van Der Helm
Estimating the term…
The present invention relates to novel vaccines against malaria infections, based on recombinant adenovirus vectors. Described are capsid modified replication deficient adenovirus particle encoding and displaying circumsporozoite (CS) protein NANP-repeats (CSshort) from a malaria-causing parasite, preferably P. falciparum, via a minor capsid protein IX and encoding a heterologous protein as a transgene. In a particular embodiment, said replication incompetent vectors of rare serotypes such as human adenovirus 35 (HAdV35) and human adenovirus 26 (HAdV26) comprise nucleic acid encoding the CS protein, as a transgene, from a malaria-causing parasite and encoding and displaying the NANP-repeat from a malaria-causing parasite (1) directly fused to the protein IX, (2) fused to protein IX via a flexible linker or (3) an alpha-helical viral origin spacer SP1 to ensure both humoral and cellular responses against the selected antigens.
A recombinant adenoviral vector comprising a nucleic acid encoding a capsid comprising a fusion protein consisting of a protein IX and a fragment of a circumsporozoite (CS) protein of Plasmodium falciparum, wherein said fragment comprises the amino acid sequence of SEQ ID NO:1.
Dependencies are inferred from the claim text.